Latest advances in treatment for non-small cell lung cancer - The Lancet
WEBMar 4, 2024 · For advanced stage NSCLC, the number of EMA-approved targeted therapies for patients with metastatic lung cancer have increased rapidly over the past two decades and is expected to continue to grow quickly in the future.
Tagrisso Approved for Unresectable, Stage III, EGFR-Mutant NSCLC …
WEB1 day ago · The US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) to treat adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has ...
Lung cancer treatment: Pfizer's Lorbrena extends life in ... - NBC News
WEBMay 31, 2024 · Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a ...
Mathematical model identifies effective drug combinations for …
WEB1 day ago · Mathematical model identifies effective drug combinations for non-small-cell lung cancer. by Houston Methodist. Multiscale mechanistic model. Model schematic shows the key transport processes ...
FDA Approves Osimertinib for Unresectable NSCLC - Medscape
WEB1 day ago · IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung Cancer Immune-Related Adverse Events Linked to Longer Survival in Patients With Non-Small Cell Lung Cancer ...
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
WEBJul 10, 2024 · The drug lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with advanced non-small cell lung cancer (NSCLC) that has changes in the ALK gene, according to new results from a global clinical trial.
New promises and challenges in the treatment of advanced non …
WEBAug 6, 2024 · Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance.
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating ...
WEB3 days ago · Non-Small Cell Lung Cancer. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell ...
FDA approves neoadjuvant nivolumab and platinum-doublet …
WEBOn March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell...
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
WEBApr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC).